CryoLife, Inc. (CRY)

20.87 +0.83 (+4.14%) At close: 4:00PM EST

CryoLife, Inc.

1655 Roberts Boulevard N.W.
Kennesaw, GA 30144
United States
770 419 3355
http://www.cryolife.com

Sector(s): Healthcare
Industry: Medical Devices
Full-time employees: 1,200

Key executives

Name	Title	Pay	Exercised	Year born
Mr. James Patrick Mackin	Chairman, Pres & CEO	1.33M	N/A	1967
Mr. David Ashley Lee CPA, CPA	Exec. VP, COO & CFO	712.66k	420.47k	1965
Ms. Jean F. Holloway	Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec.	551.04k	453.38k	1957
Mr. John E. Davis	Sr. VP of Global Sales & Marketing	514.88k	N/A	1965
Mr. Michael S. Simpson	Sr. VP of Regulatory Affairs & Quality Assurance	571.22k	N/A	1968
Ms. Amy D. Horton CPA, CPA	VP & Chief Accounting Officer	N/A	N/A	1970
Mr. Matthew A. Getz	VP of HR	N/A	N/A	1969
Mr. Thomas J. Bogenschütz	Sr. VP of Europe, Middle East & Africa	N/A	N/A	1967
Joshua Wells	Sr. Director of Bus. Devel.	N/A	N/A	N/A
Karen K. Dabbs	Assistant Corp. Sec.	N/A	N/A	N/A

Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

CryoLife, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita OPEN PLUS, a hybrid stent graft system. The company also provides E-xtra DESIGN ENGINEERING products, a range of stent graft systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G, a stent graft system for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac, a stent graft used to treat aneurysmal iliac arteries, as well as aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, it offers vascular preservation services; synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products, such as YAG laser consoles, related service and maintenance, and single-use, fiber-optic handpieces; and CryoVein femoral vein and CryoArtery femoral artery vascular preservation services for vascular access. The company serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. CryoLife, Inc. was founded in 1984 and is headquartered in Kennesaw, Georgia.

Corporate governance

CryoLife, Inc.’s ISS governance QualityScore as of 1 November 2019 is 2. The pillar scores are Audit: 1; Board: 4; Shareholder rights: 3; Compensation: 2.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.